MorphoSys AG : to Present at Jefferies 2012 Global Healthcare Conference in June
05/30/2012| 08:35am US/Eastern
Recommend:
MorphoSys AG /
MorphoSys to Present at Jefferies 2012 Global Healthcare Conference in June
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will present at the upcoming Jefferies 2012 Global Healthcare Conference in New York.
Jefferies 2012 Global Healthcare Conference
Date: June 07, 2012, 01:00 pm EDT (07:00 pm CEST, 06:00 pm BST)
Venue: New York, USA
Participants: Dr. Simon Moroney, CEO of MorphoSys AG
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR
The PDF version of the presentation will be provided at www.morphosys.com:
http://www.morphosys.com/. A link to the webcast is filed under www.morphosys.com/conference-calls:
http://www.morphosys.com/conference-calls.
On May 31, 2012, the Annual General Meeting 2012 of MorphoSys AG will take place in Munich. The management's presentation (in German) will be broadcast online at
10:00 am CEST under www.morphosys.com/agm:
http://www.morphosys.com/agm.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The Company's AbD Serotec:
http://www.abd-serotec.com/ unit uses HuCAL and other technologies to generate superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline:
http://www.morphosys.com/pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on engineering the medicines of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com:
http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors@morphosys.com:
mailto:investors@morphosys.com
Conference Announcement:
http://hugin.info/130295/R/1615845/515185.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
HUG#1615845
Recommend :
